As European markets experience a rally, with the STOXX Europe 600 Index climbing over 3% amid easing geopolitical tensions, investors are increasingly focused on identifying value opportunities within this buoyant environment. In such conditions, a good stock is often characterized by its potential to be undervalued relative to intrinsic estimates, offering a promising avenue for those seeking to capitalize on market optimism while maintaining an eye toward long-term fundamentals.
Top 10 Undervalued Stocks Based On Cash Flows In Europe
| Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|---|---|---|---|
| SP Group (CPSE:SPG) |
DKK386.00 |
DKK764.09 |
49.5% |
| SinterCast (OM:SINT) |
SEK89.20 |
SEK178.10 |
49.9% |
| Serviceware (XTRA:SJJ) |
€12.50 |
€24.67 |
49.3% |
| Qrf Comm. VA (ENXTBR:QRF) |
€11.05 |
€22.10 |
50% |
| Multiconsult (OB:MULTI) |
NOK163.40 |
NOK325.76 |
49.8% |
| LapWall Oyj (HLSE:LAPWALL) |
€3.99 |
€7.92 |
49.6% |
| Cint Group (OM:CINT) |
SEK4.00 |
SEK7.93 |
49.6% |
| B&S Group (ENXTAM:BSGR) |
€5.85 |
€11.66 |
49.8% |
| Apotea (OM:APOTEA) |
SEK64.85 |
SEK129.21 |
49.8% |
| Airbus (ENXTPA:AIR) |
€170.46 |
€336.19 |
49.3% |
Below we spotlight a couple of our favorites from our exclusive screener.
SP Group
Overview:SP Group A/S, with a market cap of DKK4.53 billion, manufactures and sells moulded plastic and composite components across various regions including Denmark, Europe, the Americas, Asia, the Middle East, Australia, and Africa.
Operations:The company's revenue primarily comes from its Plastics & Rubber segment, which generated DKK2.95 billion.
Estimated Discount To Fair Value:49.5%
SP Group is trading 49.5% below its estimated fair value of DKK 764.09, highlighting significant undervaluation based on discounted cash flow analysis. Despite high debt levels and recent insider selling, earnings are forecast to grow at a robust 21.3% annually, outpacing the Danish market's growth rate. Recent results show modest revenue and net income increases for 2025, with future revenue projected between DKK 3.4 billion and DKK 3.6 billion in 2026, indicating strong financial prospects despite challenges.
Zaptec
Overview:Zaptec ASA develops and sells chargers, charging systems, and services for electric car charging across Norway, Sweden, Switzerland, Denmark, Iceland, the rest of Europe, and internationally with a market cap of NOK2.82 billion.
Operations:Zaptec ASA's revenue is primarily derived from the development and sale of electric car charging solutions, including chargers, systems, and related services across various international markets.
Estimated Discount To Fair Value:14.6%
Zaptec is trading at NOK 32.45, slightly below its estimated fair value of NOK 37.99, suggesting some undervaluation based on cash flows. The company reported strong financial results for 2025, with net income reaching NOK 53.89 million compared to a loss the previous year and initiated a dividend policy reflecting solid liquidity. While revenue growth is slower than ideal at 12.4% annually, earnings are expected to grow significantly at over 35% per year, outpacing the Norwegian market's profit growth rate of 11.9%.
-
Insights from our recent growth report point to a promising forecast for Zaptec's business outlook.
-
Click here to discover the nuances of Zaptec with our detailed financial health report.
Elekta
Overview:Elekta AB (publ) is a medical technology company specializing in clinical solutions for treating cancer and brain disorders across various regions, with a market cap of approximately SEK21.15 billion.
Operations:Elekta's revenue segments include SEK5.74 billion from the Asia Pacific, SEK4.57 billion from the Americas, and SEK6.81 billion from Europe, the Middle East, and Africa.
Estimated Discount To Fair Value:41.7%
Elekta is trading at SEK 55.35, well below its estimated future cash flow value of SEK 94.92, highlighting its undervaluation potential based on cash flows. Despite a challenging third quarter with net income dropping to SEK 10 million from SEK 341 million year-over-year, the company is expected to become profitable within three years and achieve earnings growth of over 34% annually. Recent FDA clearance for Elekta Evo CT-Linac enhances its market position in radiation therapy innovation.
-
Click here and access our complete balance sheet health report to understand the dynamics of Elekta.
Key Takeaways
-
Click this link to deep-dive into the 184 companies within our Undervalued European Stocks Based On Cash Flows screener.
-
Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
-
Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Want To Explore Some Alternatives?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CPSE:SPG OB:ZAP and OM:EKTA B.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
